Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-CoV-2 vector vaccines in a cohort of 400 health care workers
Vaccine-induced immune thrombotic thrombocytopenia (VITT) was reported after adenovector-based COVID-19 vaccination with ChAdOx1 and Ad26.COV2 ·S as a rare, but very severe complication [1,2]. Thrombosis/hypercoagulation has been reported also as a common complication of (severe) COVID-19 and is probably multifactorial due to endothelial dysfunction caused either by direct viral infection or by hyperinflammation which also leads to activa tion of platelets and the clotting cascade as well as due to alteration of the blood flow, as explained by the Virchow's triad [3].
Source: Thrombosis Research - Category: Hematology Authors: Wagner Angelika, Garner-Spitzer Erika, Kundi Michael, Stockinger Hannes, Pabinger Ingrid, Eichinger-Hasenauer Sabine, Quehenberger Peter, Wagner Oswald, Wiedermann Ursula, Grabmeier-Pfistershammer Katharina Tags: Letter to the Editors-in-Chief Source Type: research
More News: Covid Vaccine | COVID-19 | Health Management | Hematology | SARS | Thrombocytopenia | Thrombosis | Vaccines